# Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

> **NCT00042458** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 296 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Pramlintide acetate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00042458
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00042458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00042458, "Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00042458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*